Hai-Yan Qu1, Ya-Wei Xiao, Gui-Hua Jiang, Zhi-Yun Wang, Yun Zhang, Mei Zhang. 1. The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Shandong University Qilu Hospital, No. 107#, Jinan, Shandong, 250012, China.
Abstract
PURPOSE: To compare the short-term effect of treatment with atorvastatin and rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. METHODS:Sixty-nine patients with hypercholesterolemia were randomly assigned to receive 10 mg/day of atorvastatin or rosuvastatin for 12 weeks. Inflammatory biomarkers, including highsensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-alpha, matrix metalloproteinase-9 (MMP-9), and endothelin (ET-1), plasminogen activator inhibitor type 1 (PAI-1) and plasma tissue plasminogen activator (tPA), adiponectin, and lipid profiles were measured before and after statin therapy. RESULTS:Atorvastatin and rosuvastatin both lowered levels of hs-CRP, MMP-9, PAI-1, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) from baseline values, with rosuvastatin lowering TC and LDL-C to a greater extent than atorvastatin (P < 0.05). Adiponectin level increase was 15% higher than that at baseline with atorvastatin (P > 0.05) but 67% higher with rosuvastatin (P < 0.05). CONCLUSIONS: Therapy with both statins not only significantly improved lipid profiles but also decreased levels of vascular biomarkers hs-CRP, MMP-9, and PAI-1; however, only rosuvastatin increased serum adiponectin levels significantly in patients with hypercholesterolemia, which could imply a beneficial effect in coronary artery disease.
RCT Entities:
PURPOSE: To compare the short-term effect of treatment with atorvastatin and rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. METHODS: Sixty-nine patients with hypercholesterolemia were randomly assigned to receive 10 mg/day of atorvastatin or rosuvastatin for 12 weeks. Inflammatory biomarkers, including highsensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-alpha, matrix metalloproteinase-9 (MMP-9), and endothelin (ET-1), plasminogen activator inhibitor type 1 (PAI-1) and plasma tissue plasminogen activator (tPA), adiponectin, and lipid profiles were measured before and after statin therapy. RESULTS:Atorvastatin and rosuvastatin both lowered levels of hs-CRP, MMP-9, PAI-1, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) from baseline values, with rosuvastatin lowering TC and LDL-C to a greater extent than atorvastatin (P < 0.05). Adiponectin level increase was 15% higher than that at baseline with atorvastatin (P > 0.05) but 67% higher with rosuvastatin (P < 0.05). CONCLUSIONS: Therapy with both statins not only significantly improved lipid profiles but also decreased levels of vascular biomarkers hs-CRP, MMP-9, and PAI-1; however, only rosuvastatin increased serum adiponectin levels significantly in patients with hypercholesterolemia, which could imply a beneficial effect in coronary artery disease.
Authors: I V Sergienko; E Iu Samoĭlenko; V P Masenko; M V Ezhov; A B Sumarokov; G A Tkachev; O A Pogorelova; T V Balakhonova; V G Naumov Journal: Kardiologiia Date: 2006 Impact factor: 0.395
Authors: Ioanna Gouni-Berthold; Heiner K Berthold; John P Chamberland; Wilhelm Krone; Christos S Mantzoros Journal: Clin Endocrinol (Oxf) Date: 2007-10-31 Impact factor: 3.478
Authors: K Miyagishima; S Hiramitsu; S Kato; Y Kato; F Kitagawa; R Teradaira; R Shinohara; K Mori; H Kimura; T Ueda; M Ohtsuki; S Morimoto; H Hishida Journal: J Int Med Res Date: 2007 Jul-Aug Impact factor: 1.671
Authors: Kevin J Molloy; Matt M Thompson; Edward C Schwalbe; Peter R F Bell; A Ross Naylor; Ian M Loftus Journal: Am J Cardiol Date: 2004-07-01 Impact factor: 2.778
Authors: Sun Young Choi; Jong Sung Park; Mee Sook Roh; Chong-Rak Kim; Moo Hyun Kim; Victor Serebruany Journal: Lipids Date: 2017-05-04 Impact factor: 1.880
Authors: Anne Huotari; Soili M Lehto; Leo Niskanen; Karl-Heinz Herzig; Jukka Hintikka; Heli Koivumaa-Honkanen; Tommi Tolmunen; Kirsi Honkalampi; Noora Kaikkonen; Heimo Viinamäki Journal: Cardiovasc Psychiatry Neurol Date: 2010-03-14
Authors: Sayer I Al-Azzam; Asem M Alkhateeb; Karem H Alzoubi; Raya N Alzayadeen; Mera A Ababneh; Omar F Khabour Journal: Exp Ther Med Date: 2013-10-15 Impact factor: 2.447